FarmPharma signs agreement with Testa Center
FarmPharma AB, which is subsidiary to Double Bond Pharmaceutical AB, has today signed a cooperation agreement with GE Healthcare to implement a project at Testa Center in Uppsala. As previously announced, FarmPharma has been granted financial means for this project within the framework of the "BioProcess Innovation Center" from Vinnova. The work is expected to start during the summer this year and last for three weeks. The purpose of the project is to test the manufacturing procedure of InterferOX components on a larger scale to facilitate the successful transition to industrial GMP manufacturing of the product.
"We have been looking forward to this for some time and are very happy that our cooperation is now real", - comments Iulia Karlsson, CEO of FarmPharma. - Ge Healthcare is very experienced in our industry and has a lot of expertise relevant to our project, which will both ensure the quality and speed up our product development. ”
More about Testa Center: https://testacenter.com/
More about InterferOX: www.farmpharma.se
This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 24 of May 2019.
For more info, contact
Igor Lokot, CEO
Homepage: http://www.doublebp.com/
E-mail: info@doublebp.com
Blog: http://blog.doublebp.com
Follow us on LinkedIn, Facebook and Twitter!
Information on Double Bond Pharmaceutical International AB
DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline. DBP has during the past year also started two subsidiaries, Drugsson AB for the distribution of fully developed human pharmaceutical and medical device products and dietary supplements in Scandinavia, and FarmPharma AB for the development of innovative veterinary products.
Tags: